Deficient IL-2 production contributes to the immune system observed in SLE.21 Notably, low-dose IL-2 has shown efficacy and tolerability in SLE treatment by fostering regulatory T (Treg) cells and inhibiting Th17 and Tfh cells.22–24 To optimize the treatment of SLE, it is desirable to minimize the inhibition of IL-2 when targeting CD132. Here, IL2 is linked to systemic lupus erythematosus.